The categories section serves as a knowledge base for Pharma-watch.com on Drugs and Medical Devices. Over the past couple of months the FDA has released several consumer alerts on drugs such as Hydroxycut, Accutane and Paxil to name a few; and on medical devices such as Zimmer Durom Cut, Shoulder Pain Pumps, and Fentanyl Patch. We bring all the information together in one place to give you — the consumer– the ability to make an educated and well informed decision about the drugs you are putting in your body.
(March 1, 2012) Pick 10 people at random and ask them if they take sleeping pills. Chances are at least one of them is, according to new research – research that suggests the lone adult taking those pills is up to five times more likely than the other nine to die prematurely.
Are storm clouds already gathering over Pradaxa?Critics of blood-thinner drug troubled by events in New Zealand
(Oct. 18, 2011) If some safety advocates are correct, a drug worth keeping a skeptical eye on is the blood thinner Pradaxa because of its propensity to increase the risk of bleeding – perhaps fatally so, according to the manufacturer’s own label warning.Already, in New Zealand, Pradaxa is tied to at least two deaths amid reports that scores of elderly users there experienced bleeding ranging from mild to severe.
(Oct. 19, 2011) CareFusion Corp. today announced that its voluntary recall of 128 EnVe ventilators made late last year through May has received a U.S. Food & Drug Administration designation of Class 1 – meaning the government believes there is a potentially lethal injury risk to patients connected to the affected devices.
European Medicines Agency remains cautious toward pioglitazone, but hesitates to issue outright ban despite Actos bladder cancer evidence
(Oct. 25, 2011) After earlier sending signals that it might move to outlaw the drug pioglitazone (Actos), the European Medical Agency backed off last week from recommending any such ban on the grounds that Type 2 diabetics who respond only to this particular pharmaceutical should not lose access to it, despite mounting evidence linking Actos to bladder cancer.
The U.S. Food & Drug Administration has revoked its approval of Avastin after concluding the metastatic breast cancer treatment did nothing to control tumor growth or help patients live longer, but instead increased their risk of developing severe high blood pressure, hemorrhages and other serious side effects.